The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors.
 
Anthony W. Tolcher
Stock and Other Ownership Interests - Symphony Evolution
Consulting or Advisory Role - AbbVie; Adnexus; Ambit BioSciences; AP Pharma; Aragon Pharmaceuticals; ARIAD; ArQule; Asana Biosciences; Astellas Pharma; Astex Pharmaceuticals; AVID Radiopharmaceuticals; Bayer Schering Pharma; Bind Therapeutics; BioMed Valley Discoveries; Blend Therapeutics; Bristol-Myers Squibb; Celator; Clovis Oncology; Curis; Dicerna; Eisai; Emergent BioSolutions; Heron; Janssen; Johnson & Johnson; Lilly; MedImmune; Merck Sharp & Dohme; Merus; Micromet; Nanobiotix; Nektar; Neumedicines; Novartis (I); Oncogenex; Pfizer; Pharmacyclics; Pierre Fabre; ProNAi; Proximagen; Symphony Evolution; Vaccinex; Valent Technologies; Zyngenia; Zyngenia
 
Kyriakos P. Papadopoulos
No Relationships to Disclose
 
Amita Patnaik
Research Funding - Dicerna
 
Drew Warren Rasco
Research Funding - Celgene; Daiichi Sankyo; Five Prime Therapeutics; Millennium; Rexahn Pharmaceuticals; Santa Maria Biotherapeutics; Teva
 
Dorothy Martinez
No Relationships to Disclose
 
Debra L Wood
Employment - Nadler Pharma Associates
Leadership - Nadler Pharma Associates
Stock and Other Ownership Interests - Hansen Medical; Vanda Pharmaceuticals
Consulting or Advisory Role - Aurigene Discovery Technologies; Dicerna; OncoTherapy Science; PRISM Pharma
 
Barbara Fielman
Employment - AVEO; Dicerna
Stock and Other Ownership Interests - AVEO; Dicerna
 
Manish Sharma
No Relationships to Disclose
 
Linda A. Janisch
No Relationships to Disclose
 
Bob D Brown
Employment - Dicerna
Leadership - Dicerna
Stock and Other Ownership Interests - Dicerna
Consulting or Advisory Role - Roche
Patents, Royalties, Other Intellectual Property - Dicerna
Expert Testimony - Roche
 
Pankaj Bhargava
Employment - Dicerna; Sanofi
Leadership - Dicerna
Stock and Other Ownership Interests - Dicerna; Sanofi
 
Mark J. Ratain
Stock and Other Ownership Interests - AspenBio Pharma; Biscayne Pharmaceuticals
Consulting or Advisory Role - AbbVie; Agios; Biscayne Pharmaceuticals; Cantex Pharmaceuticals; Cerulean Pharma; Cyclacel; Daiichi Sankyo; EMD Serono; Genentech/Roche; Kinex; Onconova Therapeutics; Sanofi; Shionogi; XSpray Microparticles AB
Research Funding - Bristol-Myers Squibb (Inst); Dicerna (Inst); OncoTherapy Science (Inst); PharmaMar (Inst)
Patents, Royalties, Other Intellectual Property - pending patent related to a genomic prescribing system; pending patent related to a genomic prescribing system (Inst); royalties related to UGT1A1 genotyping for irinotecan; royalties related to UGT1A1 genotyping for irinotecan (Inst)
Expert Testimony - Apotex; Fresenius Kabi; Mylan; Teva